Amyloidosis Center News
The 2019 Annual Meeting of the Massachusetts Chapter, ACC will be Saturday, October 12, 2019
Dr. Omar Siddiqi and Dr. Vaishali Sanchorawala educating cardiologists about cardiac amyloidosis on Saturday, October 12, 2019, in Waltham, MA at the Massachusetts chapter of American College of Cardiology.
ATTR Amyloidosis: Best Practices and Emerging Therapies
ATTR Amyloidosis: Best Practices and Emerging Therapies Deepa Gopal, MD, MS Assistant Professor of Cardiovascular Medicine Michelle Kaku, MD Assistant Professor of Neurology
The 17th International Myeloma Workshop in Boston
Plenary session on Amyloidosis at the 17th international myeloma workshop in Boston, September 12-15, 2019
Congratulations to Lisa Mendelson, NP
Lisa Mendelson, NP in the Amyloidosis Center was selected as a recipient for the 2019 Boston University Medical Group (BUMG) Award. She will be inducted into the BUMG Clinical Excellence Society. We are so proud of Lisa!
Congratulations to Dr. Sarosiek
Shayna Sarosiek, MD to receive Junior Faculty Mentoring Award of the Department of Medicine. This award recognizes Excellence in Mentoring of Peers and Trainees by a Junior faculty member in the Department.
Congratulations to Dr. Havasi
Dr. Andrea Havasi, nephrologist in the Amyloidosis Center, has been awarded Evans Clinician award of the Department of Medicine. Congratulations to Dr. Havasi
Amyloidosis Support Group Meeting
Amyloidosis Support Group Meeting
2020 Amyloidosis House LHHS Report
There was a recent large increase of funding for NIH, The House Appropriations Committee has also reported on a bill that contains very positive language on Amyloidosis. 2020 Amyloidosis House LHHS Report Language HOUSE APPROPRIATIONS COMMITTEE FISCAL YEAR 2020 LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION H.R. 2740, H Report 116-62 May 15, 2019 REPORT LANGUAGE TITLE... More
FDA Approves New Treatments
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatments-heart-disease-caused-serious-rare-disease-transthyretin-mediated "This is an epic moment for the treatment of ATTR amyloidosis. We are very excited and hopeful for the expanding landscape of ATTR amyloidosis by the approval of tafamidis, the first drug approved for ATTR cardiomyopathy. Tafamidis will have a tremendous impact on patients with both hereditary and wildtype ATTR... More
Amyloidosis Center Research
http://sites.bu.edu/gareth-morgan/